These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 16162203)

  • 1. Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients.
    Vítko S; Margreiter R; Weimar W; Dantal J; Kuypers D; Winkler M; Øyen O; Viljoen HG; Filiptsev P; Sadek S; Li Y; Cretin N; Budde K;
    Am J Transplant; 2005 Oct; 5(10):2521-30. PubMed ID: 16162203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study.
    Lorber MI; Mulgaonkar S; Butt KM; Elkhammas E; Mendez R; Rajagopalan PR; Kahan B; Sollinger H; Li Y; Cretin N; Tedesco H;
    Transplantation; 2005 Jul; 80(2):244-52. PubMed ID: 16041270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Everolimus (Certican) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients.
    Vítko S; Margreiter R; Weimar W; Dantal J; Viljoen HG; Li Y; Jappe A; Cretin N;
    Transplantation; 2004 Nov; 78(10):1532-40. PubMed ID: 15599319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Everolimus with reduced cyclosporine versus MMF with standard cyclosporine in de novo heart transplant recipients.
    Lehmkuhl HB; Arizon J; Viganò M; Almenar L; Gerosa G; Maccherini M; Varnous S; Musumeci F; Hexham JM; Mange KC; Livi U;
    Transplantation; 2009 Jul; 88(1):115-22. PubMed ID: 19584690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group.
    Sollinger HW
    Transplantation; 1995 Aug; 60(3):225-32. PubMed ID: 7645033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mycophenolate mofetil for the treatment of a first acute renal allograft rejection: three-year follow-up. The Mycophenolate Mofetil Acute Renal Rejection Study Group.
    Mycophenolate Mofetil Acute Renal Rejection Study Group
    Transplantation; 2001 Apr; 71(8):1091-7. PubMed ID: 11374408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized trial of everolimus-facilitated calcineurin inhibitor minimization over 24 months in renal transplantation.
    Cibrik D; Silva HT; Vathsala A; Lackova E; Cornu-Artis C; Walker RG; Wang Z; Zibari GB; Shihab F; Kim YS
    Transplantation; 2013 Apr; 95(7):933-42. PubMed ID: 23422495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lower incidence of cytomegalovirus infection with everolimus versus mycophenolate mofetil in de novo cardiac transplant recipients: a randomized, multicenter study.
    Viganò M; Dengler T; Mattei MF; Poncelet A; Vanhaecke J; Vermes E; Kleinloog R; Li Y; Gezahegen Y; Delgado JF;
    Transpl Infect Dis; 2010 Feb; 12(1):23-30. PubMed ID: 19744284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Everolimus versus mycophenolate mofetil in heart transplantation: a randomized, multicenter trial.
    Eisen HJ; Kobashigawa J; Starling RC; Pauly DF; Kfoury A; Ross H; Wang SS; Cantin B; Van Bakel A; Ewald G; Hirt S; Lehmkuhl H; Keogh A; Rinaldi M; Potena L; Zuckermann A; Dong G; Cornu-Artis C; Lopez P
    Am J Transplant; 2013 May; 13(5):1203-16. PubMed ID: 23433101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of everolimus in de novo renal recipients: initial experience in the Greek population.
    Papanikolaou V; Vrochides D; Margari P; Imvrios G; Papagiannis A; Giakoustidis D; Fouzas I; Antoniadis N; Ouzounidis N; Ntinas A; Vergoulas G; Miserlis G; Solonaki F; Takoudas D
    Transplant Proc; 2008 Nov; 40(9):3166-9. PubMed ID: 19010223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic evaluation of everolimus and mycophenolate mofetil versus azathioprine in de novo heart transplantation.
    Annemans L; Lemkuhl H; Tenderich G; Schulz U; Yang XL; Ricci JF; Hetzer R
    Transplant Proc; 2007 Dec; 39(10):3306-12. PubMed ID: 18089377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclosporine lowering with everolimus versus mycophenolate mofetil in heart transplant recipients: long-term follow-up of the SHIRAKISS randomized, prospective study.
    Potena L; Prestinenzi P; Bianchi IG; Masetti M; Romani P; Magnani G; Fallani F; Coccolo F; Russo A; Ponticelli C; Rapezzi C; Grigioni F; Branzi A
    J Heart Lung Transplant; 2012 Jun; 31(6):565-70. PubMed ID: 22341702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups.
    Halloran P; Mathew T; Tomlanovich S; Groth C; Hooftman L; Barker C
    Transplantation; 1997 Jan; 63(1):39-47. PubMed ID: 9000658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective clinical trial comparing two immunosuppressive regimens, tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine, in de novo renal transplant recipients: results at 6 months follow-up.
    Favi E; Citterio F; Spagnoletti G; Gargiulo A; Delreno F; Romagnoli J; Castagneto M
    Transplant Proc; 2009 May; 41(4):1152-5. PubMed ID: 19460503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early steroid withdrawal and optimization of mycophenolic acid exposure in kidney transplant recipients receiving mycophenolate mofetil.
    Le Meur Y; Thierry A; Glowacki F; Rerolle JP; Garrigue V; Ouali N; Heng AE; Delahousse M; Albano L; Lang P; Couzi L; Jaureguy M; Lebranchu Y; Mousson C; Glotz D; Kessler M; Vrtovsnik F; Rouanet S; Tagieva N; Kamar N
    Transplantation; 2011 Dec; 92(11):1244-51. PubMed ID: 22067312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group.
    Transplantation; 1996 Apr; 61(7):1029-37. PubMed ID: 8623181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. One-Year Multicenter Double-Blind Randomized Clinical Trial on the Efficacy and Safety of Generic Cyclosporine (Iminoral) in De Novo Kidney Transplant Recipients.
    Khatami SM; Taheri S; Azmandian J; Sagheb MM; Nazemian F; Razeghi E; Shahidi S; Sadri F; Shamshiri AR; Sayyah M
    Exp Clin Transplant; 2015 Jun; 13(3):233-8. PubMed ID: 26086833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conversion of stable ABO-incompatible kidney transplant recipients from mycophenolate mofetil with standard exposure calcineurin inhibitors (CNIs) to everolimus with very low exposure CNIs-a short-term pilot study.
    Uchida J; Machida Y; Iwai T; Kuwabara N; Kabei K; Naganuma T; Kumada N; Kawashima H; Nakatani T
    Clin Transplant; 2014 Jan; 28(1):80-7. PubMed ID: 24329776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients.
    Sommerer C; Suwelack B; Dragun D; Schenker P; Hauser IA; Witzke O; Hugo C; Kamar N; Merville P; Junge M; Thaiss F; Nashan B;
    Kidney Int; 2019 Jul; 96(1):231-244. PubMed ID: 31027892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Observational study with everolimus (Certican) in combination with low-dose cyclosporine in de novo heart transplant recipients.
    Lehmkuhl HB; Mai D; Dandel M; Knosalla C; Hiemann NE; Grauhan O; Huebler M; Pasic M; Weng Y; Meyer R; Rothenburger M; Hummel M; Hetzer R
    J Heart Lung Transplant; 2007 Jul; 26(7):700-4. PubMed ID: 17613400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.